首页> 外文期刊>Antiviral Research >Hepatitis B virus reverse transcriptase sequence variant database for sequence analysis and mutation discovery.
【24h】

Hepatitis B virus reverse transcriptase sequence variant database for sequence analysis and mutation discovery.

机译:乙型肝炎病毒逆转录酶序列变异数据库,用于序列分析和突变发现。

获取原文
获取原文并翻译 | 示例
       

摘要

Drug resistance resulting from reverse transcriptase (RT) mutations is one of the main obstacles to successful hepatitis B virus (HBV) therapy. Indeed, HBV treatment guidelines recommend HBV genotypic resistance testing for patients receiving nucleos(t)ide RT inhibitors (N(t)RTIs) who develop virological failure. N(t)RTI-resistance mutations at 10 RT positions have been well characterized in phenotypic studies, however, data are lacking on the relative frequency of these mutations in N(t)RTI-treated and untreated individuals. There are also few published data on the extent of amino acid variation at most of the 344 positions of HBV RT and the extent to which this variation is influenced by N(t)RTI treatment. We retrieved 23,871 HBV RT sequences from GenBank and reviewed the published reports of these sequences to ascertain the number of individuals from whom the sequences were obtained, the N(t)RTI treatments of these individuals, and the year and region of virus sampling. We then used these data to populate a relational database we named HBVrtDB. As of July 2010, HBVrtDB contained 6811 sequences from 3869 individuals reported in 281 references. Among these 3869 individuals, 73% were N(t)RTI-naive and 27% received one or more N(t)RTIs. Among the 10 well-characterized N(t)RTI-resistance mutations, L80I/V, V173L, L180M, A181T, T184S, S202G and M204I/V were significantly associated with treatment with lamivudine, an l-nucleoside analog, and A181S/T/V and N236T were significantly associated with treatment with adefovir, an acyclic nucleoside phosphonate. A similar analysis of ten additional less well-characterized resistance mutations demonstrated a significant association with N(t)RTI treatment for four of the mutations: L82M, S85A, A200V, and Q215S. We also created an interactive program, HBVseq, to enable users to identify mutations in submitted sequences and retrieve the prevalence of these mutations in HBVrtDB according to genotype and N(t)RTI treatment. HBVrtDB and HBVseq are available at http://hivdb.stanford.edu/HBV/releaseNotes/.
机译:由逆转录酶(RT)突变引起的耐药性是成功治疗乙型肝炎病毒(HBV)的主要障碍之一。确实,HBV治疗指南建议接受接受病毒学检测的核苷(t)ide RT抑制剂(N(t)RTIs)患者进行HBV基因型耐药性检测。在表型研究中已经很好地表征了在10个RT位置的N(t)RTI抵抗突变,但是,在N(t)RTI治疗和未治疗的个体中,这些突变的相对频率缺乏数据。关于HBV RT的344个位置中大多数位置的氨基酸变异程度以及该变异受N(t)RTI处理影响的程度,也几乎没有公开的数据。我们从GenBank中检索了23,871个HBV RT序列,并审查了这些序列的公开报告,以确定从中获得该序列的个体数量,这些个体的N(t)RTI治疗以及病毒采样的年份和区域。然后,我们使用这些数据来填充一个名为HBVrtDB的关系数据库。截至2010年7月,HBVrtDB包含281个参考文献中报告的3869个个体的6811个序列。在这3869个个体中,有73%为纯N(t)RTI,有27%接受了一个或多个N(t)RTI。在10个特征明确的N(t)抗性突变中,L80I / V,V173L,L180M,A181T,T184S,S202G和M204I / V与拉米夫定,一种L-核苷类似物和A181S / T显着相关/ V和N236T与阿德福韦(一种无环核苷膦酸酯)治疗显着相关。对另外十个表征欠佳的抗药性突变的类似分析表明,对于四个突变:L82M,S85A,A200V和Q215S,与N(t)RTI处理存在显着关联。我们还创建了一个交互式程序HBVseq,以使用户能够根据基因型和N(t)RTI治疗识别提交序列中的突变并检索HBVrtDB中这些突变的普遍性。 HBVrtDB和HBVseq可从http://hivdb.stanford.edu/HBV/releaseNotes/获得。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号